Stockwatch: Reading The Entrails Of Biotech Vaccine Development
Expectations Remain Far Too High For A Coronavirus Vaccine From Biotech
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
You may also be interested in...
Hepatitis B vaccine's favorable efficacy data relative to GSK's Engerix-B and neutral safety language mean that any partnership opportunity 'would need to be a highly attractive one to alter our current course,' Dynavax CEO Gray says.
After a CDC advisory committee recommends against the nasal flu vaccine's use in any setting, sponsor AstraZeneca looks to reconcile its effectiveness results with government findings.
GlaxoSmithKline has disclosed that it has so far received worldwide orders for 440 million doses of pandemic influenza A (H1N1) vaccine, an increase of 149 million doses on figures it released in August. However, other key manufacturers of pandemic H1N1 vaccines have not released aggregate figures to date.